Total Neoadjuvant Treatment Plus PD-1 in Mid-Low Locally Advanced Rectal Cancer (STARS-RC03)
Latest Information Update: 23 Nov 2023
At a glance
- Drugs Tislelizumab (Primary)
- Indications Adenocarcinoma; Carcinoma; Rectal cancer
- Focus Adverse reactions
- Acronyms STARS-RC03
- 14 Nov 2023 Planned End Date changed from 1 Jun 2028 to 1 Jun 2026.
- 14 Nov 2023 Status changed from not yet recruiting to active, no longer recruiting.
- 01 Jul 2023 Trial design, presented at the 25th World Congress on Gastrointestinal Cancer